Gilead Sciences, Inc. GILD

150.93 1.24 0.83% as of 25 Sep
Market cap
$183.2B
P/E
0.0×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Gilead Sciences, Inc. (GILD) P/S ratio

As of 25 September 2026, Gilead Sciences, Inc. (GILD) trades at a P/S ratio of 6.2×. Over the past ten years it has ranged from 2.6× (June 2022) to 6.6× (June 2015); the current reading is higher than 97% of that period. That is above the Drug Manufacturers General industry median of 3.3× and above the Healthcare sector median of 3.8×.

P/S ratio, daily

Annual

Period P/S ratio Change
FY2025 5.2× 29.46%
FY2024 4.0× 4.56%
FY2023 3.8× (2.47%)
FY2022 3.9× 17.61%
FY2021 3.3× 12.60%
FY2020 3.0× (19.31%)
FY2019 3.7× 0.19%
FY2018 3.7× (1.09%)
FY2017 3.7× 13.53%
FY2016 3.3× (28.01%)

Quarterly

Period P/S ratio Change
Jun 2026 5.2× (11.42%)
Mar 2026 5.8× 12.25%
Dec 2025 5.2× 9.33%
Sep 2025 4.7× (0.81%)
42 more quarters

Against its own ten years

Low 2.6× High 6.6×
Ten-year median 3.7×
Current reading's percentile 97

P/S ratio against peers

Company P/S ratio
SNY Sanofi compare 1.7×
GSK GSK PLC Sponsored ADR compare 2.2×
PFE Pfizer Inc. compare 2.6×
BMY Bristol Myers Squibb Company compare 2.6×
NVO Novo Nordisk A/S compare 3.3×
AZN AstraZeneca PLC compare 4.2×
NVS Novartis AG compare 4.9×
AMGN Amgen Inc. compare 5.9×
GILD Gilead Sciences, Inc. 6.2×
Drug Manufacturers General industry median 3.3×
Healthcare sector median 3.8×
Market median 2.0×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on GILD